
Rucaparib Findings Highlight Need for More Data in BRCA+ Ovarian Carcinoma
Final overall survival (OS) analysis and other post-progression outcomes from the phase 3 ARIEL4 trial (NCT02855944), which evaluated rucaparib (Rubraca) vs standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma, …